Stevens-Johnson syndrome and toxic epidermal necrolysis from pathologist’s point of view
Authors:
Eva Sticová 1; Jitka Kyclová 2; Miroslav Důra 3; Jiří Štork 3; Břetislav Lipový 4
Authors‘ workplace:
Ústav patologie 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha
1; Ústav patologie, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice Brno
2; Dermatovenerologická klinika 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
3; Klinika popálenin a plastické chirurgie, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice Brno
4
Published in:
Čes.-slov. Patol., 59, 2023, No. 3, p. 124-128
Category:
Reviews Article
Overview
Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome) are rare diseases characterized by rapid blistering followed by extensive skin and mucosal exfoliation and constitutional symptoms. In most cases, drugs are the main triggers, but the etiopathogenesis of the diseases is not fully understood. Lyell syndrome is associated with a high mortality rate, reported to be around 35%. Therefore, early diagnosis requiring close interdisciplinary cooperation is essential. The diagnosis based on the clinical picture and a detailed pharmacological history should be confirmed by histopathological examination of the skin specimen, including analysis by direct immunofluorescence.
Keywords:
direct immunofluorescence – toxic epidermal necrolysis – Lyell syndrome – Stevens-Johnson syndrome – histopathological examination
Sources
- Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas) 2021; 57(9): 895.
- Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68(11): 355-61.
- Guvenir H, Arikoglu T, Vezir E, Misirlioglu ED. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. Curr Pharm Des 2019; 25: 3840–3854.
- Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens-Johnson syndrom / Toxic Epidermal Necrolysis—Diagnosis and treatment. JDDG J Ger Soc Dermatol 2020; 18: 547–553.
- Chaby G, Maldini C, Haddad C, Lebrun-Vignes B, et al. Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: A four-source capture-recapture estimate. Br. J. Dermatol 2020; 182: 618–624.
- Surowiecka A, Barańska-Rybak W, Strużyna J. Multidisciplinary Treatment in Toxic Epidermal Necrolysis. Int J Environ Res Public Health 2023; 20(3): 2217.
- Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2012; 166(3): 575-600.
- Jones B, Vun Y, Sabah M, et al. Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol 2005; 46: 187–191.
- Sniderman JD, Cuvelier GD, Veroukis S, et al. Toxic epidermal necrolysis and hemophagocytic lymphohistiocytosis: a case report and literature review. Clin Case Rep 2015; 3: 121–125.
- Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 201; 12: 118.
- Amstutz U, Shear NH, Rieder MJ, Hwang S, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55(4): 496-506.
- Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res 2020; 9: F1000 Faculty Rev-612.
- Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2): 149–153.
- Fu Y, Gregory DG, Sippel KC, Bouchard CS, Tseng SC. The ophthalmologist‘s role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis. Ocul Surf 2010; 8(4): 193-203.
- Hosaka H, Ohtoshi S, Nakada T, Iijima M. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis. J Dermatol 2010; 37(5):407-412.
- Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005; 141: 683–687.
- Iwai S, Sueki H, Watanabe H, Sasaki Y, et al. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically. J Dermatol 2012; 39(9):781-786.
- Valeyrie-Allanore L, Bastuji-Garin S, Guégan S, Ortonne N, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol 2013; 68(2): e29-35.
- Sauerbrey W. Zur Wesensfrage der sekundären am Beispiel eines Lyell-Syndroms [The nature of secondary milia on the example of Lyell‘s syndrome]. Z Haut Geschlechtskr 1972; 47(15): 621-624.
- King T, Helm TN, Valenzuela R, Bergfeld WF. Diffuse intraepidermal deposition of immunoreactants on direct immunofluorescence: a clue to the early diagnosis of epidermal necrolysis. Int J Dermatol 1994; 33(9): 634-636.
- Cohen AD, Cagnano E, Halevy S. Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis. Int J Dermatol 2001; 40: 458–461.
- Copaescu AM, Bouffard D, Masse MS. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review. Allergy Asthma Clin Immunol 2020; 16: 9.
- Hague JS, Kaur MR, Hafiji J, Carr RA, et al. Two cases of pustular toxic epidermal necrolysis. Clin Exp Dermatol 2011; 36(1): 42-45.
- Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int 2019; 68(3): 301-308.
- Owen CE, Jones JM. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis). Med Clin North Am 2021; 105(4): 577-597.
- Patel S, John AM, Handler MZ, Schwartz RA. Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. Am J Clin Dermatol 2020; 21(3): 393-399.
- Nguyen JK, Koshelev MV, Gill BJ, Boulavsky J, et al. A toxic epidermal necrolysis-like presentation of linear IgA bullous dermatosis treated with dapsone. Dermatol Online J 2017; 23(8): 13030/qt4443157h.
- Pereira AR, Moura LH, Pinheiro JR, et al. Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis. An Bras Dermatol 2016; 91: 35–38.
- Jordan KS. Staphylococcal Scalded Skin Syndrome: A Pediatric Dermatological Emergency. Adv Emerg Nurs J 2019; 41(2): 129-134.
- Tseng HC, Wu WM, Lin SH. Staphylococcal scalded skin syndrome in an immunocompetent adult, clinically mimicking toxic epidermal necrolysis. J Dermatol 2014; 41: 853–854.
- Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid. J Allergy Clin Immunol 2020; 145(4): 1031-1047.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
![Issue 3](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/bb64d3e5915b1217cb2fec97febd2e89.jpg)
2023 Issue 3
Most read in this issue
- Clinical and histopathological aspects of the most common inflammatory non-infectious skin diseases
- Stevens-Johnson syndrome and toxic epidermal necrolysis from pathologist’s point of view
- Tall cell carcinoma of the breast with reversed polarity - a report of three cases with a review of the literature
- Diagnostic Pitfalls in Dermatopathology